Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects
Authors:
- C. BotsiosCBC. Botsios
- P. OstuniPOP. Ostuni
- P. SfrisoPSP. Sfriso
- A. FurlanAFA. Furlan
- U. FioccoUFU. Fiocco
- D. SgarabottoDSD. Sgarabotto
- S. TodescoSTS. Todesco
Open Access
- 12 September 2011
- journal article
- abstracts
- Published by PAGEPress Publications in Reumatismo
- Vol. 55 (4) , 224-235
Abstract
Different animal studies show that several proinflammatory cytokines are essential for natural resistance to specific infections, particularly versus intracellular organisms. However, uncontrolled overproduction of some proinflammatory cytokines, in diseases such as rheumatoid arthritis, can be just as dangerous to the host as the absence of the same cytokines. Reduction in the production and/or activities of proinflammatory cytokines in rheumatoid arthritis remains a therapeutic objective for many patients. The tumour necrosis factor-alpha (TNF-α) blockers infliximab, etanercept and adalimumab and the recombinant interleukin 1 (IL-1) receptor antagonist anakinra are effective in patients with active rheumatoid arthritis. However, there is a growing body of clinical evidence that neutralization of TNF-α is associated with an increased risk of opportunistic infections, including mycobacterial diseases. Blockade of IL-1 activity with the IL-1 receptor antagonist (IL-1Ra) appears, at present, to be relatively safe. Postmarketing experience and pharmacovigilance programs are necessary to determine the overall safety profile of the new agents. At this time, treating physicians must weigh carefully the benefits of biologics against their safety, particularly in patients at risk of infection.Keywords
This publication has 45 references indexed in Scilit:
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Predictors of infection in rheumatoid arthritisArthritis & Rheumatism, 2002
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based studyArthritis & Rheumatism, 2002
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosisThe Journal of Pathology, 2000
- Lymphotoxin-β-Deficient Mice Show Defective Antiviral ImmunityVirology, 1999
- Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disordersArthritis & Rheumatism, 1989
- Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatismArthritis & Rheumatism, 1988
- Computer analysis of factors influencing frequency of infection in systemic lupus erythematosusArthritis & Rheumatism, 1978
- Acute Septic Arthritis Complicating Chronic Rheumatoid ArthritisJAMA, 1966